Nanotechnology and narasin: a powerful combination against acne

Area of Science:

• Dermatology and Pharmaceutical Sciences
• Antimicrobial Drug Development
• Nanotechnology in Drug Delivery

Background:

• Acne vulgaris is a prevalent skin disorder driven by Cutibacterium acnes (C. acnes).
• Novel antibacterial therapies are needed to combat drug-resistant C. acnes strains.
• Developing effective drug delivery systems is crucial for treating acne.

Purpose of the Study:

• To evaluate the antibacterial efficacy of narasin (NAR) against drug-resistant C. acnes.
• To formulate self-nanomicellizing solid dispersions (SNMSD) of NAR for enhanced skin delivery.
• To investigate the ex vivo skin deposition and permeation of NAR from micellar formulations.

Main Methods:

• Antibacterial activity testing of NAR against C. acnes.
• Formulation of NAR-loaded SNMSD using Soluplus®.
• Characterization of micelle size and drug loading.
• Ex vivo skin permeation and deposition studies using porcine ear skin.
• Stability assessment of the NAR-micelle gel formulation.

Main Results:

• NAR demonstrated significant antibacterial activity against C. acnes (MIC range ≤0.008-0.062).
• SNMSD formulation increased NAR aqueous solubility by 100-fold.
• NAR micelle formulations showed superior deposition into stratum corneum and epidermis compared to NAR solution.
• The optimized gel formulation was stable for 4 weeks.

Conclusions:

• Narasin is a promising agent against antimicrobial-resistant C. acnes.
• Micelle nanocarriers effectively enhance the solubility and skin delivery of poorly water-soluble drugs like NAR.
• SNMSD offers a targeted delivery approach for lipophilic skin environments, potentially improving acne treatment.